Targeting the B cell receptor pathway in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2362-2370

  Davids, Matthew S ^a   Brown, Jennifer R ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Lymphoid leukemia; Prognostication; Signaling therapies

Indexed keywords

AVL 292; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; EVEROLIMUS; FOSTAMATINIB; IBRUTINIB; IDELALISIB; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C BETA; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; RITUXIMAB; UNCLASSIFIED DRUG; XL 147;

BINDING AFFINITY; CALCIUM MOBILIZATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG TARGETING; FOLLOW UP; HEPATOSPLENOMEGALY; HUMAN; IC 50; LYMPHOCYTOSIS; MICROENVIRONMENT; MOLECULAR INTERACTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UPREGULATION; X LINKED AGAMMAGLOBULINEMIA;

ANIMALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84868370689     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.695781     Document Type: Review

References (69)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. The New England journal of medicine 2005;352:804-815.
2. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-3375.
3. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology/the Education Program of the American Society of Hematology. Am Soc Hematol Educ Prog 2011;96-103.
4. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103:4389-4395. (Pubitemid 38745961)
5. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-574.
6. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Seminars in cancer biology 2010;20:424-430.
7. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115: 2578-2585.
8. Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010;116:2201-2207.
9. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-594.
10. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107:13075-13080.
11. Tsubata T, Wienands J. B cell signaling. Introduction. Int Rev Immunol 2001;20:675-678.
12. Reth M. Antigen receptors on B lymphocytes. Annu Rev Immunol 1992;10:97-121.
13. Shinohara H, Kurosaki T. Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling. Immunol Rev 2009;232:300-318.
14. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nature reviews. Immunology 2006;6:283-294.
15. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008;111:2230-2237. (Pubitemid 351451430)
16. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. British journal of haematology 2006;132:303-316. (Pubitemid 43381537)
17. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one third of chronic lymphocytic leukemia: towards a molecular classification with implications for targeted therapeutic interventions. Blood 2012.
18. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995;378:303-306.
19. Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995;378:298-302.
20. Chen L, Chen G, Fecteau J, Coffey G, Prussak C, et al. Highly Specific Inhibitor for Syk Induces Chronic Lymphocytic Leukemia Cell Apoptosis. ASH. Volume 641; 2011.
21. Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine-and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010; 115:4497-4506.
22. Hoellenriegel J, Coffey GP, Sinha U, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2012.
23. Suljagic M, Longo PG, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood;116:4894-4905.
24. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated infl ammation. J Pharmacol Exp Ther 2006;319:998-1008.
25. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58: 3309-3318.
26. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1999;17:1244.
27. Giles FJ, Albitar M. Mammalian target of rapamycin as a therapeu tic target in leukemia. Current molecular medicine 2005;5:653-661. (Pubitemid 41824228)
28. Decker T, Hipp S, Ringshausen I, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101: 278-285. (Pubitemid 36025919)
29. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-2783.
30. Huang S, Shu L, Dilling MB, et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Molecular cell 2003;11:1491-1501. (Pubitemid 36776536)
31. Ringshausen I, Peschel C, Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leukemia & lymphoma 2005;46:11-19.
32. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Annals of hematology 2009;88:221-227.
33. Ramadani F, Bolland DJ, Garcon F, et al. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Science signaling 2010;3:ra60.
34. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18:1391-1400. (Pubitemid 39136749)
35. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-855.
36. Niedermeier M, Hennessy BT, Knight ZA, et al. Isoformselective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009;113:5549-5557.
37. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603-3612.
38. Herman SE, Lapalombella R, Gordon AL, et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011;117:4323-4327.
39. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078-2088.
40. Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM, et al. CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110d Demonstrates Clinical Activity and Pharmacodynamic Effects in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. ASH. Volume 116; 2010.
41. Sharman J, de Vos S, Leonard J, Furman R, et al. A Phase 1 Study of the Selective PI3K Inhibitor CAL-101 (GS-1101) in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory CLL. ASH. Volume 642; 2011.
42. Martin AL, Schwartz MD, Jameson SC, Shimizu Y. Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. Journal of immunology 2008;180:2081-2088.
43. Edelman G, Bedell G, Shapiro SS, Pandya, EL, Cwak, C. et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients with advanced malignancies. ASCO. Volume 28; 2010.
44. Brown JR, Davids, MS, Rodon J, Abrisqueta, P, DeCillis, AP, et al. Phase I Trial of SAR245408 (S08), a Pan-PI3K Inhibitor, in Patients with CLL and Lymphoma. ASH. Volume 623; 2011.
45. Papadopoulos, K.P, Abrisqueta, M.D, Chambers, G, et al. A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), an Orally Administered PI3K/mTOR Inhibitor in Patients with Lymphoma. Blood. 2011;118. Abstract 1608.
46. Lorusso P, Markman J, Tabernero R, Shazer L, Heath E, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. ASCO. Volume 27:15s; 2009.
47. De Weers M, Brouns GS, Hinshelwood S, et al. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. The Journal of biological chemistry 1994;269:23857-23860. (Pubitemid 24300906)
48. De Weers M, Mensink RG, Kraakman ME, Schuurman RK, Hendriks RW. Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Human molecular genetics 1994;3:161-166. (Pubitemid 24038159)
49. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-6296.
50. Ponader S, Chen SS, Buggy JJ, et al. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2011.
51. Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012.
52. Genevier HC, Hinshelwood S, Gaspar HB, et al. Expression of Bruton's tyrosine kinase protein within the B cell lineage. European journal of immunology 1994;24:3100-3105.
53. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2: 58-61.
54. Burger JA, O'Brien S, Fowler N, Advani R, Sharman J, et al. The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies. ASH; 2010.
55. O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. ASH. Volume 642; 2011.
56. Evans E, Tester P, Aslanian S, Chaturvedi P, Mazdiyasni H, et al. Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies. ASH. Volume 604; 2011.
57. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-4614. (Pubitemid 35429705)
58. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-4951. (Pubitemid 36857758)
59. Richardson SJ, Matthews C, Catherwood MA, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:3584-3592.
60. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
61. Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008;112:782-792.
62. Coscia M, Pantaleoni F, Riganti C, et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2011;25:828-837.
63. Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV. Human macrophage infl ammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. The Journal of experimental medicine 1993;177:1821-1826.
64. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113:3050-3058.
65. Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114:1029-1037.
66. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. The New England journal of medicine 2011;365:2497-2506.
67. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-105.
68. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature genetics 2012;44:47-52.
69. Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research 2011;17:2977-2986.